Herpes simplex infectious disease

Summary

Herpes simplex infectious disease (MONDO:0004609) is a disease (an umbrella term covering 10 Mondo subtypes) with 1 GWAS associations across 11 studies. A subtype of Herpesviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 10 Mondo subtypes
• GWAS associations: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	herpes simplex infectious disease
Mondo ID	MONDO:0004609
EFO	EFO:1002022
MeSH	D006561
DOID	DOID:8566
ICD-10-CM	B00
SNOMED CT	88594005
UMLS	C0019348
MedGen	9234
Is cancer (heuristic)	no

Also known as: Simplexvirus caused disease or disorder · Simplexvirus disease or disorder · Simplexvirus infectious disease

Data availability: 1 GWAS association (11 studies).

Disease family

This is a subtype of Herpesviridae infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Herpesviridae infectious disease › herpes simplex infectious disease

Related subtypes (7): herpetic gastritis, Epstein-Barr virus infection, cytomegalovirus infection, human herpesvirus 8 infection, varicella zoster infection, roseolovirus infectious disease, congenital herpes virus infection

Subtypes (10): herpetic whitlow, herpes simplex dermatitis, genital herpes, herpes simplex virus gingivostomatitis, herpes simplex encephalitis, herpes simplex virus keratitis, congenital herpes simplex virus infection, herpes labialis, herpes simplex type 1 infectious disease, herpes simplex type 2 infectious disease

Genetics & variants

GWAS landscape

1 GWAS associations across 11 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs57828624	6e-07	LINC02505	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90477052	Verma A	2024	9,980	431,401	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473046	UK Biobank Whole-Genome Sequencing Consortium	2025	4,798	453,642	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90477051	Verma A	2024	3,882	114,698	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480952	Verma A	2024	3,882	114,698	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90652179	Liu TY	2025	2,041	190,942	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90477050	Verma A	2024	1,625	56,623	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90079548	Backman JD	2021	1,285	382,676	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083534	Backman JD	2021	1,285	382,676	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90018639	Sakaue S	2021	772	166,603	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90018859	Sakaue S	2021	313	351,740	A cross-population atlas of genetic associations for 220 human phenotypes.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs57828624	4	36456619	G>A,C	0.05	intron_variant	LINC02505	6e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Acyclovir	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Trifluridine	Approved (phase 4)
Amenamevir	Phase 3 (in late-stage trials)
Famciclovir	Phase 3 (in late-stage trials)
Valacyclovir	Phase 3 (in late-stage trials)
Vidarabine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Docosanol, Edetic Acid, Glutamine, Glycine, QS-21.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.